[{"id":"e5aa0f89-24de-40bf-8a67-186c3db1a88b","acronym":"ARC-2","url":"https://clinicaltrials.gov/study/NCT03719326","created_at":"2021-01-18T18:13:45.819Z","updated_at":"2024-07-02T16:35:01.152Z","phase":"Phase 1","brief_title":"A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies","source_id_and_acronym":"NCT03719326 - ARC-2","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • pegylated liposomal doxorubicin • eganelisib (IPI-549) • etrumadenant (AB928) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 10/15/2018","start_date":" 10/15/2018","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/02/2021","study_completion_date":" 07/02/2021","last_update_posted":"2024-05-24"},{"id":"0542097c-f373-45a9-8aee-8c7560f9b729","acronym":"MARIO-3","url":"https://clinicaltrials.gov/study/NCT03961698","created_at":"2021-01-18T19:29:39.309Z","updated_at":"2024-07-02T16:35:40.372Z","phase":"Phase 2","brief_title":"Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma","source_id_and_acronym":"NCT03961698 - MARIO-3","lead_sponsor":"Infinity Pharmaceuticals, Inc.","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • albumin-bound paclitaxel • eganelisib (IPI-549)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 12/17/2019","start_date":" 12/17/2019","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2023-08-10"},{"id":"a7069631-5a6c-4c6d-b80d-c3ff1abc9085","acronym":"","url":"https://clinicaltrials.gov/study/NCT02637531","created_at":"2021-01-18T12:49:44.221Z","updated_at":"2024-07-02T16:36:14.125Z","phase":"Phase 1","brief_title":"A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549","source_id_and_acronym":"NCT02637531","lead_sponsor":"Infinity Pharmaceuticals, Inc.","biomarkers":" HER-2 • ER • ALK • PGR • MSI","pipe":" | ","alterations":" MSI-H/dMMR • ER negative • PGR negative","tags":["HER-2 • ER • ALK • PGR • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • eganelisib (IPI-549)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 219","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-04-04"}]